|
    ACIU U.S.: Nasdaq

    AC Immune S.A.

    ACIUUS
    After Hours
    Last Updated: Oct 22, 2021 5:28 p.m. EDT Delayed quote

    $ 5.98

    -0.05 -0.83%
    After Hours Volume: 17.19K
    Close Chg Chg %
    $6.03 -0.01 -0.17%
    Advanced Charting
    Volume: 213.27K 65 Day Avg: 1.95M
    11% vs Avg
    5.90 Day Range 6.05
    4.42 52 Week Range 12.61

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ACIU Overview

    Performance

    5 Day
    • -2.43%
    1 Month
    • -12.74%
    3 Month
    • -19.17%
    YTD
    • 16.63%
    1 Year
    • 20.84%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 3 Full Ratings

    Recent News

    AC Immune Shares Rally on Renewed Hope for Semorinemab in Alzheimer's >ACIU

    AC Immune: Semorinemab Meets Co-Primary Endpoint in Alzheimer's Disease >ACIU

    AC Immune Updates on Vaccine Candidates in Alzheimer's Disease

    AC Immune stock price target raised to $8.00 from $5.50 at UBS

    AC Immune stock price target cut to $4 from $16 at UBS

    AC Immune downgraded to neutral from buy at UBS

    AC Immune started at buy with $16 stock price target at UBS

    AC Immune started at outperform with $18 stock price target at Leerink

    Read full story

    Charting the Market

    Read full story

    Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’

    AC Immune SA surges 11% on presentation of Eli Lilly Alzheimer's drug trial results

    Read full story

    What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors

    AC Immune started at outperform with $22 stock price target at Leerink Partners

    Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate

    on Zacks.com

    Alzheimer's Drug for Roche Partner AC Immune Shows Promise

    on GuruFocus.com

    AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

    on Zacks.com

    Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More

    on Zacks.com

    AC Immune Jumps 16.3% on Partial Success in Alzheimer’s Drug Trial

    on TipRanks.com

    Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU) and Immutep (IMMP)

    on TipRanks.com

    Here's Why AC Immune Stock Is Surging Today

    on Motley Fool

    H.C. Wainwright Remains a Buy on AC Immune SA (ACIU)

    on TipRanks.com

    AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

    on Zacks.com

    Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to Decline

    on Zacks.com

    AC Immune SA (ACIU) Receives a Buy from Leerink Partners

    on TipRanks.com

    Analysts Are Bullish on These Healthcare Stocks: Arena Pharma (ARNA), AC Immune SA (ACIU)

    on TipRanks.com

    Leerink Partners Reiterates Their Buy Rating on AC Immune SA (ACIU)

    on SmarterAnalyst

    H.C. Wainwright Reiterates Their Buy Rating on AC Immune SA (ACIU)

    on SmarterAnalyst

    AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates

    on Zacks.com

    AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade

    on Zacks.com

    AC Immune SA (ACIU) Gets a Buy Rating from Leerink Partners

    on SmarterAnalyst

    AC Immune SA (ACIU) Gets a Buy Rating from H.C. Wainwright

    on SmarterAnalyst

    H.C. Wainwright Remains a Buy on AC Immune SA (ACIU)

    on SmarterAnalyst

    Biotech Stock Roundup: REGN's Drug Approval & Pipeline Updates From AMGN, BLUE

    on Zacks.com

    AC Immune S.A.

    AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

    Competitors

    Name Chg % Market Cap
    Ono Pharmaceutical Co. Ltd. ADR 1.48% $10.81B
    Omeros Corp. 0.46% $405.6M
    Competitor Data Provided ByCapital Cube Logo